blood were quick frozen at -80°C. All relevant information about the tumours, e.g. size, node status, receptor status (oestrogen receptor (ER) and progesterone receptor (PR)), ploidy and S phase fraction, was recorded by the same department. In this study 204 invasive ductal breast tumours were used as controls for LOH analysis (Huiping et al, 1998) .
DNA isolation
Salting out procedure (Miller et al, 1988) and phenol extraction methods were used to obtain DNA from whole blood and tumour samples respectively.
LOH determination
Microsatellite markers used for LOH analysis of chromosome 1p were: D1S233, D1S496, D1S209, D1S488, and D1S435. The microsatellite markers used for chromosome 3p were: D3S1211, D3S1029, D3S1217, D3S1210 and D3S1101. The markers used for 6q were: D6S262, D6S292, D6S409, D6S290 and D6S305. The markers used for 7q were: D7S518, D7S515, D7S523, D7S471 and D7S500. The markers used for 9p were: D9S156, D9S157, INFA, D9S171 and D9S104. The markers used for 11q were: D11S907, INT-2, D11S35, D11S4206, D11S925 and D11S921. The markers used for 13q were: D13S260, D13S171, D13S267, D13S219 and D13S263. The markers used for 16q were: D16S503, D16S496, D16S421, D16S545 and D16S512 for the 16q21-22.1 region containing the E-cadherin gene (Genome Database). The markers used for 17p were: D17S945, D17S921, D17S953, D17S925, D17S798 and D17S933. The markers used for 17q were: D17S800, D17S855, D17S1322, D17S579 and D17S784. The markers used for 18q were: D18S67, D18S474, D18S51, D18S70 and D18S61. The markers used for 20q were: D20S199, D20S118, D20S191, D20S119 and D20S196. The polymerase chain reaction (PCR) products were separated in an acrylamide sequencing gel and transferred to a positively charged nylon membrane, Hybond-N+ (Amersham, Aylesbury, UK) and baked for at least 2 h at 80°C. The non-radioactive detection method used to visualize the PCR products has been described previously (Vignal et al, 1993) . Autoradiograms were inspected visually by at least two reviewers, comparing the intensity of alleles from normal and tumour DNA. The absence or a significant decrease of one allele in the tumour compared to the normal reference sample was considered as LOH.
PCR-SSCP analysis
All 16 exons of E-cadherin gene were screened for inactivation mutations with a PCR-SSCP (single-strand conformation polymorphism) analysis on genomic DNA templates. The primers used in the SSCP analysis were described in Berx et al (1995a) and ordered from Pharmacia Biotech. Genomic DNA was used at 30 ng per 25 µl reaction mixture containing 5 pmol of the forward and reverse primers, 2.5 nmol of each dNTP, 0.5 units of DynaZyme polymerase. The samples were amplified in 35 cycles composed of 30 s of denaturation at 95°C, 60 s of annealing at 55-70°C, and finally 60 s of extension at 72°C. A hot start was used by adding the enzyme during the first cycle at about 72°C, after a preincubation time of 5 min at 94°C. A 4 µl aliquot of PCR products was mixed with 7 µl of formamide dye (95% formamide, 0.05% bromophenol blue and 0.05% xylene cyanol), denatured at 94°C for 10 min and snapcooled on ice. Aliquots of 2 µl were analysed simultaneously on two non-denaturing polyacrylamide gels (5% acrylamide with 2% cross-linking), either containing 5% glycerol or lacking glycerol. Electrophoresis was performed in 1 × TBE on vertical gels (390 × 330 × 0.4 mm) at 6w overnight or for 6 h at room temperature. The PCR products were visualized as the microsatellite markers.
Sequencing of PCR products
Samples with abnormal mobility bands were amplified again for 35 cycles as described above. A 5 µl aliquot of the PCR product was then incubated with 10 U exonuclease I and 2 U shrimp alkaline phosphatase to remove excess of primers and dNTPs (US70995, Amersham). Sequences of both strands were determined by thermo 
Immunohistochemical staining
Immunohistochemistry was performed on 5-µm sections from paraffin-embedded tumour tissue blocks with monoclonal antibody HECD-1 (Zymed Laboratories, South San Francisco, CA, USA) using the antigen retrieval protocol described by Hazelbag et al (1995) .
Statistical analysis
A χ 2 test was used to assess the relationship between LOH in lobular tumours and LOH in ductal tumours at 1p, 3p, 6q, 7q, 9p, 11q, 13q, 16q, 17q, 18q and 20q . We also analysed the association of LOH at different chromosome regions with the categorized prognostic variables, LOH at other chromosome regions and E-cadherin gene mutations by χ 2 test and Fisher's exact test.
RESULTS

LOH analysis
LOH by the use of polymorphic microsatellite markers at chromosomes 1p, 3p, 6q, 7q, 9p, 11q, 13q, 16q, 17p, 17q, 18q and 20q in 40 lobular tumours was analysed (Figure 1 ). LOH for these chromosome regions ranged from 17% to 100% (Tables 1 and 2 ). The highest percentage of LOH was detected at the 16q21-q22.1 region where all examined cases (31/31) were positive. Table 2 shows the χ 2 analysis comparing LOH in lobular tumours with LOH in ductal tumours investigated in our laboratory at the different chromosome regions. There was a significant association Useful  11  7  8  12  5  12  10  31  6  10  6  11  29  Total  32  32  30  32  30  32  31  31  22  24  22  30  31  %  34  22  27  38  17  38  32  100  27  42  27  37  94 +, positive LOH or staining; -, negative LOH or staining; (+), weak staining; *, somatic mutation in the E-cadherin gene; ND, not determined between lobular tumours and LOH at 16q (99.9% confidence interval). There was also a significant association between ductal tumours and LOH at 1p, 3p, 9p, 11q, 13q and 18q (Table 2) . By comparing all investigated chromosome regions in lobular breast tumours, a significant association was detected between LOH at 13q and LOH at 7q (P = 0.049) and between LOH at 13q and LOH at 11q (P = 0.049).
Mutational analysis of 40 lobular breast cancers by PCR-SSCP
We studied a set of breast cancers from 40 patients for occurrence of E-cadherin mutations. Mobility shifts were found in the amplicons 1, 2, 3, 4-5, 10, 13, 14 and 16 (Table 3) . Tumours with mutation in the E-cadherin gene, 936, 986, 1318 and 1515, show LOH at several chromosomes in addition to chromosome 16q: chromosome 1p, 7q, 9p, 11q, 13q, 17p, 18q and 20q; chromosome 11q and 13q; chromosome 7q, 11q, 13q and 18q; and chromosome 1p and 3p respectively (Table 1) .
DNA sequence analysis
By direct sequence analysis of the PCR products, five truncation mutations were identified among the 40 lobular tumours (Figure 2 and Table 3 ). Three frameshift insertions and two frameshift deletions were found, all resulting in premature downstream stop (Table 3) . Most of the insertions and deletions were rather small, causing 1-bp to 5-bp changes. Only one larger deletion of 22 bp was identified. We also identified one putative splice site mutation for exon 13 (Figure 2 and Table 3 ). In the mutated splice acceptor sequence of exon 13, GT was converted by a single base substitution to AT (Figure 2 and Table 3 ). All of the six mutations were found only once and have not been previously reported. Sequencing of DNA for blood from all six patients with mutations in breast tumours indicates that the mutations are not germline, but tumour-specific.
Besides the six mutations, we also identified nine different polymorphisms of which four have been described before (Risinger et al, 1994; Berx et al, 1995a Berx et al, , 1996 . Besides the frequent polymorphism in the intron 4, a previously unreported but frequent polymorphism (four out of 38) was identified in the intron 15 sequence from amplicon 16. Polymorphisms are shown in Table 3 .
Immunohistochemistry
Of the 31 lobular tumours analysed by immunohistochemistry, 29 (94%) showed no or reduced membrane-associated E-cadherin staining with monoclonal antibody HECD-1 and only two showed a clear membrane-associated expression of E-cadherin ( Figure 3 and Table 1 ). In particular, four samples 806, 986, 1318 and 1515 with truncation mutations plus LOH at 16q22.1 were negative or showed reduced E-cadherin protein expression (Table 3 and Figure  3 ). All lobular breast tumours lack membrane staining, while two of them show weak cytoplasmic staining.
Association analysis of the lobular breast tumours
We found an association between E-cadherin gene mutations and LOH at 13q and 16q (P = 0.05). A significant association was also found between LOH at 3p and high S phase, LOH at 9 p and low ER and PR content, LOH at 17p and aneuploidy (P = 0.033, 0.011, 0.001, 0.014 respectively). A trend was detected between LOH at 1p and tumours larger than 2 cm (P = 0.052).
DISCUSSION
In this study, LOH at 16q22.1 was detected in all lobular breast tumours examined. This is a higher rate than those reported in previous studies Skirnisdottir et al, 1995; Berx et al, 1996) presumably due to difference in the set of markers used. LOH at 16 q in lobular tumours was compared with LOH at 16 q in ductal tumours using the same microsatellite markers. The detected association suggests that the chromosome 16q22.1 region contains one or more suppressor genes particularly relevant to lobular breast carcinogenesis. LOH for the 16q22.1 region has been detected in several carcinoma types besides breast cancer, also suggesting the presence of tumour suppressor genes at this region (Tsuda et al, 1990; Bergerheim et al, 1991; Sato et al, 1991) . We also compared LOH at other chromosome regions in lobular and ductal breast tumours and found a higher LOH at 1 p, 3 p, 9 p, 11 q, 13 q and 18 q in ductal tumours, indicating a difference in genetic alterations in the two histological types of breast cancers.
The human E-cadherin gene has been mapped to chromosome 16q22.1 (Mansouri et al, 1988; Natt et al, 1989) . Its expression was reduced in several types of human carcinomas (Shimoyama et al, 1991; Bussemakers et al, 1992; Inoue et al, 1992; Umbas et al, 1992) . Mutations of the E-cadherin gene have been identified in human tumours and tumour cell lines (Becker et al, 1993 (Becker et al, , 1994 Kanai et al, 1994; Oda et al, 1994; Risinger et al, 1994; Berx et al, 1995a Berx et al, , 1996 . These observations in combination with LOH at 16q22.1 indicate that the E-cadherin gene is a tumour suppressor gene. Our data reported here consolidate the evidence for Ecadherin playing an important role as a typical tumour suppressor in lobular breast carcinomas. Since no mutations in the E-cadherin gene have been detected in tumours in the breast of the ductal histological type (Berx et al, 1996) , this provides the clearest evidence of molecular difference in the two main histological types of breast carcinomas. Nonetheless, reduced expression of E-cadherin has been found in both lobular and ductal breast cancers (Oka et al, 1993; Gamallo et al, 1996) and detection of chromosome 16q22.1 is the highest documental loss of a chromosome region in sporadic breast cancers of both histological types (Skirnisdottir et al, 1995;  this study). Two explanations of this difference are possible, either: (1) a gene other than the E-cadherin gene is the target of the 16q22.1 deletion in ductal compared to lobular carcinomas of breast cancer; or (2) the progression of ductal carcinomas is more sensitive to loss of one copy of the E-cadherin gene, and corresponding reduction of expression, than lobular breast carcinomas, where both copies need to be eliminated for further progression to malignant invasive growth. The LOH detected in this study is probably due to loss of genetic material for chromosome 16q22.1 since reduced expression of the E-cadherin is detected as well, but our method in detecting LOH does not exclude a duplication of a locus due to mitotic recombination.
Altogether, we examined 40 lobular breast tumours on the genomic level for E-cadherin mutations. Besides polymorphisms, six mutations were identified by our E-cadherin PCR/SSCP analysis. None of the mutations described here have been reported before. In agreement with the mutations reported by Berx et al (1996) , most of the mutations (5/6) were caused by frameshifts, usually resulting in premature stop codons (Table 3) . Although a large series of lobular tumours was analysed, we could not identify any non-sense mutation, in contrast with a previous report on five non-sense mutations in a series of 48 lobular tumours (Berx et al, 1995a (Berx et al, , 1996 . Besides truncation mutations we also found a splice site mutation, affecting the acceptor splice site and probably causing skipping of exon 14 (Table 3 ). This particular tumour shows a weak cytoplasmic E-cadherin staining. Becker et al (1993 Becker et al ( , 1994 have found frequent skipping of exon 8 or 9 in diffuse gastric carcinomas. It is noteworthy that exon 14 is encoding the part of the transmembrane domain necessary for binding membrane and the part of the cytoplasmic domain necessary for binding β-catenin and plakoglobin (γ-catenin) (Aberle et al, 1994 ). E-cadherins are linked to the actin cytoskeleton by the introduction of catenins, resulting in tight cell-cell adhesion (Cowin, 1994) . The aberrant transmembrane domain and cytoplasmic domain can affect the cell-cell adhesion. Interestingly, the six novel mutations were scattered over all five E-cadherin domains, including the signal and precursor sequences (Table 3) .
The various truncated E-cadherin peptides are likely to be secreted and to have some residual function which could interfere with proper cell-cell adhesion in the peritumoral tissues (Berx et al, 1996) . Furthermore, these fragments and even small decapeptides containing the HAV sequence, known to be involved in homophilic recognition, can disturb proper cell-cell adhesion (Blaschuk et al, 1990) . Therefore, it may be interesting to investigate the treatment of lobular tumours with related antibodies that can be synthesized in vitro according to the genes with truncation or splice site mutations.
For all informative lobular breast tumours, which we found to lack membrane E-cadherin expression, we identified both LOH of 16q22.1 harbouring the E-cadherin locus and mutations in the remaining allele, in accordance with the classical two-hit theory of Knudson for tumour suppressor genes (Knudson, 1985) . This supports the results reported by Berx et al (1995a Berx et al ( , 1996 . This is also supported by an association between E-cadherin gene mutations and LOH at 16q. Presumably, LOH at 13q could enhance the lobular tumour growth triggered by E-cadherin gene mutation and LOH at 16q because we also found an association between Ecadherin gene mutations and LOH at 13q. Transfection of MET/6 mouse mammary carcinoma cells, which lack E-cadherin, with an exogenous E-cadherin expression vector, resulted in tighter adhesion of multicellular spheroids and a reduced proliferative fraction in three-dimensional culture (St Croix et al, 1998) . Exposure to Ecadherin-neutralizing antibodies in three-dimensional culture simultaneously prevented adhesion and stimulated proliferation of E-cadherin transfectants as well as a panel of human colon, breast and lung carcinoma cell lines that express functional E-cadherin (St Croix et al, 1998) . From these, it can be concluded that E-cadherin, classically described as an invasion suppressor, is also a major growth suppressor.
We identified loss of or reduced E-cadherin expression in 29 out of 31 lobular breast tumours, in accordance with earlier studies (Gamallo et al, 1993; Rasbridge et al, 1993) . However, only six out of 29 lobular tumours lacking E-cadherin expression showed detectable E-cadherin mutations, suggesting that loss of one copy of the E-cadherin gene may affect the expression of the remaining allele. This is lower frequency of mutations than reported by Berx et al (1995a Berx et al ( , 1996 . The number of mutations reported here is These polymorphisms were also reported by Berx et al. (1995a). i This polymorphism was also reported by Risinger et al (1994) . j probably underestimated, either due to low efficiency of SSCP or that some tumours were lacking data from all exons. In addition to this the reduced expression may be due to transcriptional defects (Ji et al, 1997) . Synthesis of mRNA could be affected by mutations in the promoter region, or in intron located regulatory sequences, whereas stability of mRNA could be affected by mutations in the untranslated regions (Berx et al, 1996) . CpG-island overspanning intron 1 of the E-cadherin gene (Berx et al, 1995b ) was found to be densely methylated in breast cancer cell lines, and this correlated with loss of E-cadherin expression (Graff et al, 1995) . Moreover, p53 protein accumulation and c-erbB-2 protein overexpression may play a role in regulation of E-cadherin expression (Bukholm et al, 1997) .
Catenins link E-cadherin molecules to the actin cytoskeleton and lay a solid foundation for the tight cell-cell adhesion (Cowin, 1994) . Therefore, loss of or reduced catenin expression also interferes with cell-cell adhesion. Simultaneous loss of E-cadherins and catenins have been detected in invasive lobular breast cancer and lobular carcinoma in situ (De Leeuw et al, 1997) . Thus, it may be important to detect mutations in the catenin genes in lobular breast tumours or other epithelial carcinomas.
A number of studies have revealed that chromosome deletions in breast cancers may occur in preferred combinations with respect to growth advantage, e.g. 1p and 3p (Ragnarsson et al, 1996) , 7q and 1p (Kristjansson et al, 1997) , 3p and 6q (Bragadottir et al, 1995) , 9p and 6q , 13q and 17p (Anderson et al, 1992) , 11p and 17p (Takita et al, 1992) , 18q and 1p, 7q, 9p, 13q and 17q (Huiping et al, 1998) . In order to determine whether there are specific combinations of chromosome deletions in lobular breast tumours, we compared LOH at different chromosome regions and found a weak association between LOH at 13q and LOH at 7q and 11q.
LOH at different chromosome regions was compared with various clinicopathological variables of the lobular breast carcinomas. A significant association was found between LOH at 9p and low ER and low PR. This suggests that LOH at 9p could be involved in the loss of ER and PR content. A weak association was found between LOH at 3p and high S phase fractions and a trend between LOH at 1p and tumour larger than 2 cm. This suggests that genes at 3p and 1p could possibly have a restraining effect on the rate of cell proliferation, and the loss of them would lead to a rapid growth. We also found a weak association between LOH at 17p and aneuploidy, indicating that LOH at 17p could be associated with an unstable genome.
